Colorado Patent of the Month – March 2023

Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. While this method has seen great results and efficacy, research is ongoing, trying to find better and more effective solutions. GlobeImmune, Inc., a biotechnology company, has recently patented a solution using immunotherapy compositions and vaccines that elicit a cell-mediated immune response for the treatment of cancer and many infectious diseases.

The company has focused their research efforts on developing products for the treatment of cancer and infectious diseases based on their proprietary Tarmogen® platform. Tarmogens activate a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominantly stimulate antibody production.

One of the most significant challenges in treating cancer is its high mortality rate and resistance to conventional therapies. But, novel discoveries in cancer biology have led to the development of target-specific anti-cancer agents and immunotherapies that elicit a therapeutic immune response against cancer antigens in the body.

The newly patented technology relates to the use of a combination of immunotherapy compositions to prevent, ameliorate or treat cancer. The immunotherapy composition is made with a recombinant vaccinia virus made of nucleic acids with cancer antigens as well as a yeast compound which acts as a vehicle to deliver the antigens.

The development of safe and effective immunotherapy strategies and adjuvants for various diseases, including cancer, is crucial to the healthcare industry. GlobeImmune, Inc.’s immunotherapy compositions and vaccines have shown great potential in inducing a therapeutic immune response against cancer antigens and improving the survival rate of individuals with cancer.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts